Adults with type 2 diabetes will have a new alternative to daily insulin injections now that the U.S. Food and Drug Administration (FDA) approved a new once-a-week insulin injection.

People with type 2 diabetes who take insulin can switch from daily basal insulin injections to weekly injections of Onswik ...

Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora ...

The FDA approved Onswik, a once-weekly basal insulin for adults with type 2 diabetes. Here's how it works, who it's for and ...

Daily injections become once a week. For those continuing diabetes treatment, this is a change that affects daily life ...

Lilly's new once-weekly insulin, Onswik (insulin efsitora alfa-gobe), recently received FDA approval, marking a significant milestone in the diabetes care and treatment.

SUPER-1 is a 52-week (26-week main phase plus 26-week extension phase), phase 3, treat-to-target trial investigating the efficacy and safety of once-weekly GZR4 versus once-daily insulin glargine U100 ...

Ozempic from Novo Nordisk is turning into the once-weekly injection many adults with type 2 diabetes reach for when daily pills are no longer enough. With its combination of blood sugar control and ...

Mounjaro from Eli Lilly and Co. is a once-weekly GLP-1/GIP injection approved in the US for type 2 diabetes, with strong real-world interest for its weight-loss effects and growing availability in ...

Hundreds of thousands of people with type 2 diabetes could get access to a new weekly insulin jab to replace daily injections, reducing the number needed each year by 86%. Patients still have to wait ...

The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type ​2 ...

The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering an alternative to ...